IL6 and atherosclerosis: Given the conflicting experimental literature regarding atherosclerosis and effects on the myocardium ascribed to IL-6 and the complexity of IL-6 signaling, and in view of the varied actions of IL-6 based on the precise timing and location, large-scale clinical endpoint trials will be needed to determine the effects of IL-6 inhibition on cardiovascular events.